Viridian Therapeutics, Inc. (VRDN) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -483.6%, revenue growth 23359.9% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $70.85M |
| Revenue (TTM) | $0.1B |
| Net Margin | -483.6% |
| Operating Margin (TTM) | -543.9% |
| Net Debt / EBITDA | 0.4 |
| Revenue Growth (YoY) | 23359.9% |
| FCF Growth (YoY) | 18.9% |
| Price / Book | 3.94 |
| Price / Sales | 35.33 |
| FCF Yield | -25.3% |
| Altman Z-Score | 6.16 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
VRDN overview · VRDN earnings · VRDN KPIs · VRDN documents · VRDN ownership · VRDN peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.